Previous Close | 30.76 |
1-Year Change | 39.25% |
6-Months Change | 44.48% |
3-Months Change | 43.74% |
Moving Avg (50d) | 24.373 |
Moving Avg (200d) | 20.589 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.25B |
Beta (3-Years) | 1.61 |
Revenue Growth (ttm) | 207.89% |
Net Profit Margin (ttm) | -36.51% |
Return On Assets (ttm) | -10.06% |
EPS (ttm) | -0.97 |
PE Ratio (ttm) | -31.71 |
Dividend Yield | % |
Asset Description: | Denali Therapeutics Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-07-18 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
31.375 | 32.298 | 32.913 | 33.836 | 35.374 | 36.912 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.